Aberdeen Group
TEVA icon

Aberdeen Group’s Teva Pharmaceuticals TEVA Stock Holding History

Aberdeen Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.75M Sell
81,083
-82,414
-50% -$2.74M ﹤0.01% 753
2026
Q1 		$4.92M Sell
163,497
-3,512
-2% -$113K 0.01% 688
2025
Q4 		$5.21M Sell
167,009
-655,837
-80% -$16.2M 0.01% 698
2025
Q3 		$15.8M Sell
822,846
-6,519
-0.8% -$114K 0.03% 513
2025
Q2 		$13.9M Buy
829,365
+38,767
+5% +$626K 0.02% 519
2025
Q1 		$12.2M Buy
790,598
+286,206
+57% +$5.11M 0.02% 517
2024
Q4 		$11.3M Sell
504,392
-88,801
-15% -$1.62M 0.02% 484
2024
Q3 		$10.7M Sell
593,193
-87,512
-13% -$1.53M 0.02% 510
2024
Q2 		$11.1M Buy
680,705
+81,998
+14% +$1.26M 0.02% 492
2024
Q1 		$8.45M Buy
598,707
+86,721
+17% +$1.09M 0.02% 579
2023
Q4 		$5.35M Buy
511,986
+449,053
+714% +$4.19M 0.01% 657
2023
Q3 		$642K Sell
62,933
-912
-1% -$8.49K ﹤0.01% 795
2023
Q2 		$481K Sell
63,845
-3,645
-5% -$29.6K ﹤0.01% 847
2023
Q1 		$597K Buy
67,490
+8,189
+14% +$81K ﹤0.01% 826
2022
Q4 		$541K Sell
59,301
-6,205
-9% -$54.1K ﹤0.01% 833
2022
Q3 		$529K Sell
65,506
-19,524
-23% -$173K ﹤0.01% 835
2022
Q2 		$676K Sell
85,030
-19,233
-18% -$168K ﹤0.01% 831
2022
Q1 		$978K Buy
104,263
+16,493
+19% +$138K ﹤0.01% 827
2021
Q4 		$703K Sell
87,770
-11,620
-12% -$105K ﹤0.01% 926
2021
Q3 		$991K Buy
99,390
+9,214
+10% +$86.3K ﹤0.01% 886
2021
Q2 		$893K Buy
90,176
+6,430
+8% +$68.1K ﹤0.01% 890
2021
Q1 		$967K Sell
83,746
-9,433
-10% -$108K ﹤0.01% 865
2020
Q4 		$900K Sell
93,179
-68,774
-42% -$659K ﹤0.01% 840
2020
Q3 		$1.46M Sell
161,953
-6,814
-4% -$72.1K ﹤0.01% 748
2020
Q2 		$2.08M Buy
168,767
+15,921
+10% +$180K 0.01% 695
2020
Q1 		$1.37M Sell
152,846
-17,861
-10% -$183K ﹤0.01% 728
2019
Q4 		$1.67M Sell
170,707
-95,078
-36% -$849K ﹤0.01% 745
2019
Q3 		$1.83M Sell
265,785
-42,307
-14% -$324K ﹤0.01% 723
2019
Q2 		$2.84M Buy
308,092
+63,800
+26% +$769K 0.01% 696
2019
Q1 		$3.83M Buy
244,292
+199,300
+443% +$3.51M 0.01% 665
2018
Q4 		$704K Sell
44,992
-30,400
-40% -$623K ﹤0.01% 793
2018
Q3 		$1.62M Buy
75,392
+6,292
+9% +$146K ﹤0.01% 751
2018
Q2 		$1.68M Sell
69,100
-13,900
-17% -$283K ﹤0.01% 747
2018
Q1 		$1.42M Hold
83,000
– – ﹤0.01% 712
2017
Q4 		$1.57M Hold
83,000
– – ﹤0.01% 702
2017
Q3 		$1.46M Buy
+83,000
New +$1.87M ﹤0.01% 694

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Aberdeen Group's TEVA Position: Q2 2026 in Review

Aberdeen Group reduced its Teva Pharmaceuticals (TEVA) stake by 50% in Q2 2026, selling an estimated $2.74M and leaving 81,083 shares worth $2.75M. The position accounts for ﹤0.01% of the portfolio, ranked #753.

Aberdeen Group first reported a position in TEVA in Q3 2017 and has held it in 36 quarters since. The position peaked at $15.8M in Q3 2025. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Aberdeen Group held 81,083 shares of Teva Pharmaceuticals worth $2.75M as of Q2 2026.
  • Aberdeen Group sold 82,414 Teva Pharmaceuticals shares in Q2 2026, an estimated $2.74M.
  • Teva Pharmaceuticals made up ﹤0.01% of Aberdeen Group's portfolio in Q2 2026, its #753 holding.
  • Aberdeen Group first reported a position in Teva Pharmaceuticals in Q3 2017 and has held it in 36 quarters since.
  • Aberdeen Group's Teva Pharmaceuticals position peaked at $15.8M in Q3 2025.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.